Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ENGRAB

Financiado

Cerrado

Antibody engineering by natural selection and by design

Antibodies represent a powerful defense mechanism due to their capacity to link specific antigen recognition with effector functions and are currently developed as drugs for prophylaxis and therapy of infectious diseases. The gene... ver más

31/10/2025

INGM

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FONDAZIONE ISTITUTO NAZIONALE DI GENETICA MOL... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-10-29

ERC-2019-ADG: ERC Advanced Grant

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

INGM

2.48M€ | Lider

MECANIZADOS NORTE BRAVO

572.10K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AB-AG-INTERACT Learning the interaction rules of antibody-antigen binding 2M€ Cerrado

PRe-ART-2T Predictive REagent-Antibody Replacement Technology stage 2-T... 800K€ Cerrado

ABDESIGN Computational design of novel protein function in antibodies 1M€ Cerrado

PID2021-126014OB-I00 INGENIERIA DE ANTICUERPOS DIRIGIDOS A MPER MEDIANTE MODIFICA... 200K€ Cerrado

IHIVARNA Therapeutic TriMix mRNA based Vaccine in Chronic HIV 1 Inf... 8M€ Cerrado

MABSTER Monoclonal Antibodies with Binding Sensitive To Environmenta... 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2020-10-29
Fecha Fin: 2025-10-31

Líder del proyecto

FONDAZIONE ISTITUTO NAZIONALE DI GENETICA MOL... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Antibodies represent a powerful defense mechanism due to their capacity to link specific antigen recognition with effector functions and are currently developed as drugs for prophylaxis and therapy of infectious diseases. The generation of antibody diversity represents a remarkable example of protein engineering that is coupled to a stringent mechanism of clonal selection. In the ENGRAB project we propose first to develop an integrated bioinformatics platform to unravel the clonal dynamics of antibody responses and use it to formulate and test hypotheses on the factors that drive antibody selection in primary and recall responses, thus providing a rational basis for vaccination strategies. Second, we will establish the general relevance and impact of receptor-based antibodies, a new type of naturally engineered antibodies generated by templated DNA insertions into immunoglobulin genes. Third, we will use different bispecific antibody formats, including those produced by templated insertions, to engineer, in the same molecule, two binding sites for the HIV spike in order to increase neutralization potency and breadth. Fourth, we will engineer the Fc portion of antibodies to HSV, S. aureus and M. tuberculosis to increase their effector function through loss-of-binding to pathogen Fc receptors or gain-of-binding to human activatory Fc receptors. The program is strongly supported by preliminary findings and will deliver an innovative platform to interrogate natural antibody repertoires and new strategies to engineer antibodies to improve their therapeutic efficacy. The ENGRAB project deals with mechanisms of antibody diversification and engineering with implications for vaccination and immunotherapy. It is therefore submitted to LS6. Given its translational potential it also falls within the scope of LS7.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores